Ping Chiao

3.7k citations

19 papers · 436 indexed · h-index 8

Impact in

Psychiatry and Mental health top 5%
- Dementia and Cognitive Impairment Research
Physiology top 10%
- Alzheimer's disease research and treatments

Papers in ⓘ

Statistics and Probability 6
- Statistical Methods in Clinical Trials 6
Physiology 11
- Alzheimer's disease research and treatments 11

Co-authors: Tianle Chen (9 shared papers)Joyce Suhy (5 shared papers)Gregory Klein (5 shared papers)Alvydas Mikulskis (2 shared papers)Shorena Janelidze (1 shared paper)Oskar Hansson (1 shared paper)Josef Pannee (1 shared paper)Henrik Zetterberg (1 shared paper)
Journals: Alzheimer s & Dementia (9 papers)Neurology (3 papers)Sleep Medicine (1 paper)Journal of Nuclear Medicine (1 paper)Alzheimer Disease & Associated Disorders (1 paper)
Partner nations: United States Switzerland Slovakia

In The Last Decade

Ping Chiao

17 papers receiving 433 citations

Peers

Countries citing papers authored by Ping Chiao

Since Specialization

Citations

This map shows the geographic impact of Ping Chiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ping Chiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ping Chiao more than expected).

Fields of papers citing papers by Ping Chiao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ping Chiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ping Chiao. The network helps show where Ping Chiao may publish in the future.

Co-authors

The 25 scholars most cited alongside Ping Chiao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ping Chiao Line = papers co-authored together Ping Chiao links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment JAMA Neurology ·Shorena Janelidze, Josef Pannee, Alvydas Mikulskis, Ping Chiao, Henrik Zetterberg, Kaj Blennow, Oskar Hansson	2017	93
2	The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data Alzheimer s & Dementia ·Mark E. Schmidt, Ping Chiao, Gregory Klein, Dawn C. Matthews, Lennart Thurfjell, Patricia E. Cole, Richard Margolin, Susan Landau, Norman L. Foster, N. Scott Mason, Susan De Santi, Joyce Suhy, Robert A. Koeppe, William J. Jagust, (unknown)	2014	93
3	Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials Alzheimer Disease & Associated Disorders ·Jeff Sevigny, Joyce Suhy, Ping Chiao, Tianle Chen, Gregory Klein, Derk D. Purcell, Joonmi Oh, Ajay Verma, Mehul Sampat, Jerome Barakos	2016	86
4	Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab Journal of Nuclear Medicine ·Ping Chiao, Barry J. Bedell, Brian Avants, Alex Zijdenbos, Marilyn Grand’Maison, Paul O’Neill, John O’Gorman, Tianle Chen, Robert A. Koeppe	2018	39
5	Comparison of actigraphy and polysomnography to assess effects of zolpidem in a clinical research unit Sleep Medicine ·Barry T. Peterson, Ping Chiao, Eve H. Pickering, Jon Freeman, Gary Zammit, Yu Ding, Lori L. Badura	2012	34
6	O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study Alzheimer s & Dementia ·Jeff Sevigny, Ping Chiao, Leslie Williams, Tianle Chen, Ling Yan, John O’Gorman, Christoph Höck, Roger M. Nitsch, Alfred Sandrock	2015	32
7	Noninvasive PK11195‐PET Image Analysis Techniques Can Detect Abnormal Cerebral Microglial Activation in Parkinson's Disease Journal of Neuroimaging ·Yeona Kang, P. David Mozley, Ajay Verma, David J. Schlyer, Claire Henchcliffe, Susan A. Gauthier, Ping Chiao, Bin He, Anastasia Nikolopoulou, Jean Logan, Jenna M. Sullivan, Kane O. Pryor, Jacob Hesterman, Paresh J. Kothari, Shankar Vallabhajosula	2018	28
8	Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (S2.004) Neurology ·Samantha Budd Haeberlein, Sarah Gheuens, Tianle Chen, John O’Gorman, Philipp von Rosenstiel, Ping Chiao, Guanfang Wang, Christian von Hehn, LeAnne Skordos, Christoph Höck, Roger M. Nitsch, Alfred Sandrock	2018	9
9	Amyloid beta–positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity Neurobiology of Aging ·Brian Avants, R. Matthew Hutchison, Alvydas Mikulskis, Cristian Salinas-Valenzuela, Richard Hargreaves, John D. Beaver, Ping Chiao	2018	7
10	O1‐09‐06: 24‐MONTH ANALYSIS OF CHANGE FROM BASELINE IN CLINICAL DEMENTIA RATING SCALE COGNITIVE AND FUNCTIONAL DOMAINS IN PRIME: A RANDOMIZED PHASE 1B STUDY OF THE ANTI–AMYLOID BETA MONOCLONAL ANTIBODY ADUCANUMAB Alzheimer s & Dementia ·Samantha Budd Haeberlein, Carmen Castrillo‐Viguera, Sarah Gheuens, Tianle Chen, John O’Gorman, Ping Chiao, Guanfang Wang, Christian von Hehn, LeAnne Skordos, Christoph Höck, Roger M. Nitsch, Philip von Rosenstiel, Alfred Sandrock	2018	4
11	Aducanumab titration dosing regimen: 24-month analysis from PRIME, a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (S2.003) Neurology ·Philipp von Rosenstiel, Sarah Gheuens, Tianle Chen, John O’Gorman, Ping Chiao, Guanfang Wang, Christian von Hehn, LeAnne Skordos, Christoph Höck, Roger M. Nitsch, Samantha Budd Haeberlein, Alfred Sandrock	2018	3
12	Titration dosing of aducanumab: Results of a 12-month interim analysis from a randomized, double-blind, placebo-controlled Phase 1b study (PRIME) in patients with prodromal or mild Alzheimer’s Disease (S7.003) Neurology ·Vissia Viglietta, John O’Gorman, Leslie Williams, Tianle Chen, Ahmed Enayetallah, Ping Chiao, Christoph Höck, Roger M. Nitsch, Samantha Budd Haeberlein, Alfred Sandrock	2017	2
13	P1‐252: CONCORDANCE OF QUANTITATIVE SUVR METHODS WITH VISUAL ASSESSMENT OF FLORBETAPIR PET SCREENING RESULTS Alzheimer s & Dementia ·Gregory Klein, Ping Chiao, Jerome Barakos, Derk D. Purcell, Mehul Sampat, Joonmi Oh, Jeff Sevigny, Joyce Suhy	2014	2
14	P1–362: Amyloid PET screening results by APOE‐ε4 status from a phase 1b clinical study of 221AD103 in people with prodromal to mild Alzheimer's disease Alzheimer s & Dementia ·Ping Chiao, Joyce Suhy, Jerome Barakos, Meredith Burke, Gregory Klein, Jeff Sevigny	2013	1
15	P3‐212: OPTIMIZED, FULLY‐AUTOMATED CLASSIFICATION OF AMYLOID‐POSITIVE SUBJECTS BASED ON [18F]FLORBETAPIR PET SCANS Alzheimer s & Dementia ·Barry J. Bedell, Félix Carbonell, Arnaud Charil, Alex Zijdenbos, Alan C. Evans, Jeff Sevigny, Ping Chiao	2014	1
16	Segmentation by surface-to-image registration Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE ·Zhiyong Xie, José G. Tamez‐Peña, Michael A. Gieseg, Serguei Liachenko, Shantanu Dhamija, Ping Chiao	2006	1
17	O4‐07‐02: ENRICHMENT OF EARLY‐STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS Alzheimer s & Dementia ·Ping Chiao, Joyce Suhy, Jerome Barakos, Meredith Burke, Gregory Klein, Ajay Verma, Jeff Sevigny	2014	1
18	P1‐040: Clinical Dementia Rating‐Sum of Boxes Responder Analysis in Prime: A Randomized Phase 1B Study of the Anti‐Amyloid Beta Monoclonal Antibody Aducanumab (BIIB037) Alzheimer s & Dementia ·Vissia Viglietta, John O’Gorman, Leslie Williams, Tianle Chen, Ping Chiao, Brendon Boot, Christoph Höck, Roger M. Nitsch, Alfred Sandrock	2016	0
19	P1‐041: 24‐MONTH ANALYSIS OF APOE ε4 CARRIERS IN PRIME: A RANDOMIZED PHASE 1B STUDY OF THE ANTI–AMYLOID BETA MONOCLONAL ANTIBODY ADUCANUMAB Alzheimer s & Dementia ·Philip von Rosenstiel, Carmen Castrillo‐Viguera, Sarah Gheuens, Tianle Chen, John O’Gorman, Ping Chiao, Guanfang Wang, Christian von Hehn, LeAnne Skordos, Christoph Höck, Roger M. Nitsch, Samantha Budd Haeberlein, Alfred Sandrock	2018	0

About Ping Chiao

Ping Chiao is a scholar working on Statistics and Probability, Physiology, Neurology, Radiology, Nuclear Medicine and Imaging and Psychiatry and Mental health, having authored 19 papers that have together received 436 indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (11 papers), Medical Imaging Techniques and Applications (6 papers), Statistical Methods in Clinical Trials (6 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers), Dementia and Cognitive Impairment Research (4 papers), Cholinesterase and Neurodegenerative Diseases (2 papers), Neuroinflammation and Neurodegeneration Mechanisms (2 papers) and Elasticity and Material Modeling (1 paper). The work is most often cited by research in Psychiatry and Mental health (242 citations), Physiology (266 citations), Neurology (60 citations), Biological Psychiatry (13 citations) and Radiology, Nuclear Medicine and Imaging (101 citations). Ping Chiao has collaborated with scholars based in United States, Switzerland and Slovakia. Frequent co-authors include Tianle Chen, Joyce Suhy, Gregory Klein, Alvydas Mikulskis, Shorena Janelidze, Oskar Hansson, Josef Pannee, Henrik Zetterberg, Jeff Sevigny and Kaj Blennow. Their work appears in journals such as Alzheimer s & Dementia, Neurology, Sleep Medicine, Journal of Nuclear Medicine and Alzheimer Disease & Associated Disorders.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact